Anika Therapeutics, Inc. reported a 41% increase in revenue for Regenerative Solutions, surpassing expectations with the Integrity™ Implant System and strong Hyalofast® growth. Despite Hyalofast clinical trial results not meeting primary endpoints, it showed significant improvements in secondary endpoints. The company reaffirmed fiscal 2025 revenue and EBITDA guidance, adjusting long-term outlook based on potential FDA review timing for Hyalofast launch.

Anika’s second quarter revenue decreased by 8%, driven by lower pricing for Monovisc® and Orthovisc®. Integrity procedures continued to grow, with FDA clearance for new implant sizes. International OA Pain Management revenue was lower due to production yield issues. Anika is focused on resolving these issues and advancing towards NDA submission for Cingal. The company maintains 2025 revenue guidance and adjusts long-term revenue expectations based on Hyalofast launch timing.

Anika’s financial results for the quarter showed a 17% decline in operating expenses, with a loss from continuing operations. Adjusted EBITDA was negative, driven by stock-based compensation and shareholder activism costs. Adjusted net income from continuing operations showed a loss, reflecting the impact of these expenses. Anika continues to focus on product innovation and commercial growth while addressing production challenges and advancing clinical programs.

Read more at GlobeNewswire: Anika Reports Second Quarter 2025 Financial Results